AMANDA MOORE: Open Payments
NPI 1932463288 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$823 in 41 payments from 18 companies in 2025. Trend: 2023 $857 · 2024 $877 · 2025 $823
Food & beverage: $823
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $132 |
| Lilly USA, LLC | 6 | $111 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $79 |
| ABBVIE INC. | 3 | $66 |
| TOLMAR, INC. | 3 | $61 |
| Novo Nordisk Inc | 3 | $57 |
| Noven Therapeutics, LLC | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Globus Medical, Inc. | 1 | $31 |
Products named: CAPLYTA, Kerendia, JARDIANCE, REXULTI, JATENZO, Xelstrym, VRAYLAR, MOUNJARO.
Industry payments across LA — which companies pay providers there.
